...
首页> 外文期刊>Eurosurveillance >Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17
【24h】

Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17

机译:在2010/11至2016/17流感季节,英国65岁及以上人群中流感疫苗的摄取和有效性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background In 2016/17, seasonal influenza vaccine was less effective in those aged 65 years and older in the United Kingdom. We describe the uptake, influenza-associated mortality and adjusted vaccine effectiveness (aVE) in this age group over influenza seasons 2010/11–2016/17. Methods: Vaccine uptake in 2016/17 and five previous seasons were measured using a sentinel general practitioners cohort in England; the test-negative case-control design was used to estimate pooled aVE by subtype and age group against laboratory-confirmed influenza in primary care from 2010–2017. Results: Vaccine uptake was 64% in 65–69-year-olds, 74% in 70–74-year-olds and 80% in those aged 75 and older. Overall aVE was 32.5% (95% CI: 11.6 to 48.5); aVE by sub-type was 60.8% (95% CI: 33.9 to 76.7) and 50.0% (95% CI: 21.6 to 68.1) against influenza A(H1N1)pdm09 and influenza B, respectively, but only 5.6% (95% CI: -?39.2 to 35.9) against A(H3N2). Against all laboratory-confirmed influenza aVE was 45.2% (95% CI: 25.1 to 60.0) in 65–74 year olds; -?26.2% (95% CI: -?149.3 to 36.0) in 75–84 year olds and -?3.2% (95% CI: -?237.8 to 68.5) in those aged 85 years and older. Influenza-attributable mortality was highest in seasons dominated by A(H3N2). Conclusions: Vaccine uptake with non-adjuvanted, normal-dose vaccines remained high, with evidence of effectiveness against influenza A(H1N1)pdm09 and B, though poor against A(H3N2), particularly in those aged 75 years and older. Forthcoming availability of newly licensed vaccines with wider use of antivirals can potentially further improve prevention and control of influenza in this group.
机译:背景技术在2016/17年度,季节性流感疫苗在英国65岁及以上的人群中效果较差。我们描述了该年龄段在2010 / 11-2016 / 17流感季节的摄入量,与流感相关的死亡率和调整后的疫苗效力(aVE)。方法:使用英格兰前哨全科医生队列测量了2016/17年和之前五个季节的疫苗摄入量;测试阴性的病例对照设计用于估计2010-2017年间按一级和年龄组的基础医疗机构对实验室确诊流感的合并aVE。结果:65-69岁的人群中的疫苗摄入率为64%,70-74岁的人群中为74%,75岁及以上的人群中为80%。总体aVE为32.5%(95%CI:11.6至48.5);分别针对甲型H1N1)pdm09和乙型流感的aVE分别为60.8%(95%CI:33.9至76.7)和50.0%(95%CI:21.6至68.1),但仅为5.6%(95%CI) :对A(H 3 N 2)为-39.2〜35.9)。在65-74岁的人群中,所有实验室确认的流感病毒的aVE率为45.2%(95%CI:25.1至60.0);在75-84岁的人群中为-26.2%(95%CI:-149.3至36.0),在85岁以上的人群中为-3.2%(95%CI:-237.8至68.5)。在以A(H3N2)为主的季节中,归因于流感的死亡率最高。结论:非佐剂,常规剂量疫苗的疫苗摄取率仍然很高,有证据证明对A(H1N1)pdm09和B流感有效,尽管对A(H3N2)的有效性较弱,尤其是在75岁及以上的人群中。即将面市的新许可疫苗和更广泛的抗病毒药物使用可能会进一步改善该人群的流感预防和控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号